Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx

Trial Profile

Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Thiotepa (Primary) ; Treosulfan (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms TFT 2 Tx
  • Most Recent Events

    • 04 Dec 2018 Primary endpoint (To assess the probability of disease-free survival, defined as being alive and free of relapse at 1 year after 2nd allogeneic PBSCT from unrelated donors after a uniform intensive-RIC conditioning with the TFT regimen and defined GvHD prophylaxis) has been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top